Abstract
Balancing the advice from a panel of experts with federal regulatory rules is often quite difficult and sometimes takes some profound pondering, said Robert Temple, director of medical policy at FDA. On December 13, 2006, the agency asked its Psychopharmacologic Drugs Advisory Committee to discuss
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.